Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.
Ganguly S, Lone Z, Muskara A, Imamura J, Hardaway A, Patel M, Berk M, Smile TD, Davicioni E, Stephans KL, Ciezki J, Weight CJ, Gupta S, Reddy CA, Tendulkar RD, Chakraborty AA, Klein EA, Sharifi N, Mian OY. Ganguly S, et al. Among authors: gupta s. J Clin Invest. 2023 Nov 15;133(22):e165718. doi: 10.1172/JCI165718. J Clin Invest. 2023. PMID: 37966114 Free PMC article.
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Schuster J, Sheng IY, Reddy CA, Khorana AA, Nizam A, Gupta S, Gilligan T, Wee CE, Sussman TA, Bonham A, Maroli K, Martin A, Ornstein MC. Schuster J, et al. Among authors: gupta s. Clin Genitourin Cancer. 2024 Apr;22(2):92-97. doi: 10.1016/j.clgc.2023.09.005. Epub 2023 Oct 5. Clin Genitourin Cancer. 2024. PMID: 37932205
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. Schaeffer EM, et al. Among authors: gupta s. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063. J Natl Compr Canc Netw. 2022. PMID: 36509074
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. Lara PN Jr, et al. Among authors: gupta s. Eur Urol. 2024 Feb;85(2):171-176. doi: 10.1016/j.eururo.2023.03.036. Epub 2023 Apr 19. Eur Urol. 2024. PMID: 37085425 Free PMC article. Clinical Trial.
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A, Rader RK, Tzeng A, Wei W, Sheng IY, Martin A, Wee CE, Gilligan TD, Gupta S, Ornstein MC. Nizam A, et al. Among authors: gupta s. Clin Genitourin Cancer. 2024 Apr;22(2):368-379. doi: 10.1016/j.clgc.2023.12.007. Epub 2023 Dec 15. Clin Genitourin Cancer. 2024. PMID: 38245437
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. Lara PN Jr, et al. Among authors: gupta s. Prostate Cancer Prostatic Dis. 2024 Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38424319
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Li R, et al. Among authors: gupta s. Urol Oncol. 2023 Nov;41(11):457.e17-457.e24. doi: 10.1016/j.urolonc.2023.09.017. Epub 2023 Oct 23. Urol Oncol. 2023. PMID: 37880002
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Hoimes CJ, et al. Among authors: gupta s. Future Oncol. 2024 Mar;20(7):351-360. doi: 10.2217/fon-2023-0112. Epub 2023 Nov 23. Future Oncol. 2024. PMID: 37994649 Free PMC article. Review.
23,383 results
You have reached the last available page of results. Please see the User Guide for more information.